NCT02057913View on ClinicalTrials.gov

A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP)

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 17, 2014

Primary Completion Date

November 6, 2018

Study Completion Date

November 6, 2018

Conditions
Locally-advanced or Metastatic Penile Neoplasms
Interventions
DRUG

Vinflunine

All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.

Trial Locations (9)

CF14 2TL

Velindre NHS Trust, Whitchurch

TR1 3LJ

Royal Cornwall Hospitals NHS Trust, Truro

NW1 2PG

University College London Hospitals NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

SW17 0QT

St George's Healthcare NHS Trust, Tooting

CH63 4JY

Clatterbridge Centre for Oncology NHS Foundation Trust, Metropolitan Borough of Wirral

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

LS79 7TF

St James's University Hospital, Leeds

LE1 5WW

Leicester Royal Infirmary, Leicester

All Listed Sponsors
collaborator

St George's Healthcare NHS Trust

OTHER

lead

Institute of Cancer Research, United Kingdom

OTHER

NCT02057913 - A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) | Biotech Hunter | Biotech Hunter